Said Elias A
Department of Microbiology & Immunology, Faculty of Medicine, Montreal University; Montreal, Quebec, Canada; and Montreal University Hospital Research Center (CR-CHUM), St-Luc Hospital, Montreal, Quebec, Canada. Email:
Sultan Qaboos Univ Med J. 2010 Dec;10(3):312-7. Epub 2010 Nov 14.
Infection with the hepatitis C virus (HCV) is a worldwide problem. Patients with chronic HCV infection who are non-responders to standard therapy represent a growing population within the HCV epidemic. Novel, more efficient and tolerable therapies are urgently needed. This review discusses the recent results showing that targeting miR-122, a micro-ribonucleic acid (MicroRNA) that enhances HCV replication, is a new anti-HCV therapy with a high barrier to resistance.
丙型肝炎病毒（HCV）感染是一个全球性问题。对标准治疗无反应的慢性HCV感染患者在HCV流行人群中所占比例日益增加。迫切需要新型、更有效且耐受性更好的治疗方法。本综述讨论了近期的研究结果，这些结果表明，靶向miR-122（一种可增强HCV复制的微小核糖核酸）是一种新的抗HCV疗法，具有较高的耐药性屏障。
